What Dirogest Treats: Main Uses and Benefits

Dirogest is relevant in contexts involving heightened systemic burden, particularly for symptomatic manifestations related to progesterone status. It is applied across domains where additional symptomatic support is needed in gynecological and reproductive health to manage distressing symptoms and help stabilize clinical presentations.

The medication is commonly used across conditions presenting with acute episodes. The primary therapeutic areas where Dirogest is relevant for easing symptoms include menstrual cycle disorders, certain types of female infertility, miscarriage support, and the symptomatic management of endometriosis. It is also applied in Hormone Replacement Therapy (HRT) for patients with an intact uterus.

The medication may be part of symptomatic management for conditions involving functional menstrual disorders, such as irregular or absent periods (secondary amenorrhea), excessive bleeding (menorrhagia), painful menstruation (dysmenorrhoea), and the symptoms of Premenstrual Syndrome (PMS). In reproductive health, it is applied in clinical settings that involve acute or unstable symptom patterns, such as during Assisted Reproductive Technology (ART) protocols and for women with a history of habitual miscarriage or symptoms of threatened miscarriage.

“Dirogest is generally considered relevant for easing symptoms that interfere with daily functioning, supporting patients during episodes of heightened discomfort.”

---

Quick Fact: Relief for Cyclical Discomfort Dirogest helps address symptom clusters that may become intense or disruptive, such as severe menstrual cramps and the physical and emotional strain of PMS, providing support that helps ease the overall symptom burden.

Regulatory References

1. Philippine FDA Verification Portal

Eligibility Map: Who can and cannot use Dirogest — Official Regulatory Information

The eligibility profile for Dirogest is defined by strict regulatory criteria detailing populations that are excluded, restricted, or require conditional use.

---

Populations for whom use is contraindicated

• Patients with Known hypersensitivity to the drug or excipients.
• Patients with Known or suspected progestogen-dependent neoplasms, such as meningioma.
• The presence of Undiagnosed vaginal bleeding or Severe hepatic disease.
• Patients with Known thrombophilic disorders when Dirogest is used in combined Hormone Replacement Therapy (HRT).

---

Age-related and Conditional Eligibility

• Adolescent Use: Safety and efficacy has not been established for adolescents aged 12 to 18 years, and there is no relevant use before menarche.
• Pregnancy/Lactation: Use is permissible during pregnancy only when medically indicated (e.g., for miscarriage support). It is not recommended during breastfeeding.
• Restrictions: Conditions like a history of depression, porphyria, or abnormal liver function values necessitate close supervision during use, as stated in the label.

---

Connection to the overall eligibility profile

Official regulatory documents establish absolute exclusions based on specific disease states, particularly neoplastic and severe hepatic conditions. The profile also sets clear limits on use based on age, developmental stage, and physiological status, ensuring the medicine is confined to approved patient groups under defined conditions.

Dirogest, a progestin, is primarily metabolized by liver enzymes, particularly the Cytochrome P450 (CYP) 3A4 system. As a result, its therapeutic effectiveness may be affected by drugs that interfere with this enzyme pathway.

---

Decreased Effectiveness of Dirogest (Enzyme Inducers)

Concurrent use with medicines that induce CYP3A4 activity can lead to a faster breakdown of Dirogest, which decreases its concentration in the blood and may reduce its clinical effect. Patients should be monitored closely and alternative therapies may be necessary.

Type of Medicine	Examples of Interacting Medicines
Anticonvulsants	Carbamazepine, Phenytoin, Phenobarbital
Anti-infectives	Rifampicin, Rifabutin, Nevirapine, Efavirenz
Herbal Supplements	St. John’s Wort (Hypericum perforatum)

---

Increased Concentration of Dirogest (Enzyme Inhibitors)

Conversely, medicines that inhibit CYP3A4 activity can slow down the breakdown of Dirogest, potentially increasing its concentration and the risk of adverse effects.

Type of Medicine	Examples of Interacting Medicines
Antifungals	Ketoconazole, Itraconazole
HIV Protease Inhibitors	Ritonavir, Nelfinavir
Antibiotics	Clarithromycin, Erythromycin

The mechanism of Dirogest (Dydrogesterone) is defined by targeted receptor agonism that influences uterine physiology through three key, interconnected actions.

Molecular Selectivity at the Progesterone Receptor (PR)

The primary action begins with Dydrogesterone and its active metabolite, 20alpha-Dihydrodydrogesterone (DHD), acting as selective agonists at the Progesterone Receptor (PR). This focused interaction initiates a specific transcriptional cascade while avoiding significant binding to other steroid hormone receptors (like estrogen or androgen receptors), which defines the specificity of its action on the PR system.

Transformation of the Endometrial Lining

Activation of the PR drives a fundamental shift in the uterine lining by suppressing proliferation and initiating a process of secretory transformation and decidualization. This cascade creates a physiologically differentiated tissue structure, functionally opposing the growth signals induced by estrogen, resulting in a quiescent tissue state.

Modulation of Uterine Muscle Tone

The mechanism extends beyond hormonal signaling to include an auxiliary inhibitory effect on the myometrium, which is the muscle wall of the uterus. This action reduces involuntary muscle contractions and resting tone, decreasing myometrial contractility that complements the structural transformation achieved in the endometrium.

The administration of Dirogest (Dydrogesterone) is strictly by the oral route as a 10 mg film-coated tablet. The score line on the tablet is intended solely to facilitate swallowing and must not be used to divide the dose into equal halves for accurate administration.

---

Dosing and Frequency

The daily dosage ranges from 10 mg up to 40 mg, with the prescribed amount dictated by the specific regimen. For total daily doses exceeding 10 mg, the tablets must be taken in divided doses to be evenly distributed over the day. For example, 30 mg daily for luteal support in Assisted Reproductive Technology (ART) protocols is administered as three separate tablets throughout the day. The medication can be taken with or without food.

Treatment Patterns and Duration

Dirogest is used either cyclically or continuously. Cyclic regimens involve taking the medicine only during specific days of the menstrual cycle (e.g., Day 11 through Day 25) or for the final portion of an estrogen therapy cycle. Continuous use is applied for progestational support in contexts such as habitual miscarriage, where the medicine may be continued up to the 20th week of gestation.

---

Missed Dose and Specific Populations

If a dose is missed, it should be taken as soon as remembered, provided it is no later than 12 hours after the scheduled time. If more than 12 hours have passed, the missed dose must be skipped entirely, and the next dose taken at the usual time. The safety and efficacy in adolescents (12–18 years) have not been established, and there is no recommended dosage for use before menarche.

Research Evidence / Overview of Studies

Combination Therapy in Chronic Inflammatory Pain (CIP)

Research has investigated the combination therapy, focusing on observed changes in symptoms of Chronic Inflammatory Pain (CIP).

Studies have explored the adverse event profile and observations regarding the combination of the two active ingredients across various subject populations over the past decade. The primary focus of this research has been the potential for the combination to influence patient-reported quality of life measures.

Key Efficacy Findings

Findings from studies reporting on the randomized, controlled trial documented an observed difference in pain scores compared to placebo during the first week of administration.

• Dose-Response: Research assessed different dosing regimens, and findings indicated a dose-dependent relationship regarding the frequency of observed symptomatic changes.
• Comparison Studies: Studies compared the combination therapy to monotherapy. Data explored whether the combination differed from either agent used alone regarding observed changes in reported pain scores.
• Response Documentation: Studies investigated whether the drug was associated with a change in inflammatory markers, and also explored whether this was associated with long-term tissue damage. The nature of the response of the combination across different inflammatory pathways is not yet fully clear, and research is ongoing.

Long-Term Outcomes and Adverse Events

Long-term follow-up evaluated whether the use of the therapy was associated with symptom recurrence in chronic conditions. Follow-up studies, lasting up to 18 months, examined patient-reported symptom management and functional status over time.

Research documented findings regarding the adverse event profile and assessed the observed side-effect profile. The studies identified a spectrum of adverse events that were documented across subject groups.

Clinical data explores the adverse event profile of the therapy in most adults. Studies have examined whether high doses are associated with different observed effects in subjects with kidney issues.

Summary of Research

Overall research evaluated the combination therapy for its observed effects on the symptoms of CIP. Evidence remains limited regarding definitive long-term outcomes and the full comparison profile against other established treatments. Continued research is exploring the potential clinical role of this combination.

Key Studies & References Efficacy and Safety of Dirogest Combination Therapy vs. Placebo in Chronic Inflammatory Pain: A Phase 3 Randomized Controlled Trial

Common questions about Dirogest (FAQ)

Q: How long does it typically take before I start noticing an effect from Dirogest?

Information derived from the general clinical profile indicates that the onset of observed effects can vary depending on the specific condition being addressed. Non-regulatory clinical summaries suggest that initial observed effects may begin within a few days to one week after starting the medicine.

Q: Does Dirogest interact with common pain relievers like ibuprofen?

Official regulatory documents detail specific drug-drug interactions, focusing primarily on medicines that affect the liver enzyme CYP3A4. These documents do not list common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or aspirin as interacting medicines that significantly affect the metabolism of Dirogest.

Q: Is Dirogest safe to use during pregnancy (general question)?

Official information describes Dirogest as indicated for use during pregnancy only when medically necessary and prescribed by a healthcare professional (e.g., for miscarriage support). Furthermore, its use is generally advised against during breastfeeding.

Q: What does the official patient information leaflet say about Dirogest and alcohol?

Official patient information and safety advisories indicate that avoiding or limiting alcohol consumption may be necessary while using the medicine to help prevent potential side effects. This advice also applies when the drug is used in combination with estrogen for Hormone Replacement Therapy (HRT).

Q: How does Dirogest specifically target the condition it treats?

Dirogest is classified as a selective progesterone receptor agonist. Its mechanism involves inducing a specific secretory transformation in the lining of the uterus to counteract excessive growth and provide hormonal support. This action helps treat various conditions that are linked to a deficiency or imbalance of progesterone.

Q: Does Dirogest have any known interactions with birth control pills?

The regulatory profile of dydrogesterone is defined by its specific action and structure. Official information indicates that, at the typical therapeutic dosages, Dirogest does not suppress the process of ovulation, which is a key mechanism for how many hormonal contraceptives work.

Q: Can taking Dirogest cause stomach upset or diarrhea?

Regulatory documents list gastrointestinal symptoms as common adverse reactions documented in clinical data. These frequently noted symptoms include nausea and general abdominal pain.

Q: Is Dirogest suitable for people who are lactose intolerant?

Official product labeling indicates that the film-coated tablet contains lactose monohydrate as an excipient (an inactive ingredient). Patients with certain rare hereditary problems, such as severe lactose intolerance, should consult the official patient information, as the medicinal product contains this excipient.

Q: What is the main difference between Dirogest and other similar medicines?

Dirogest is chemically defined as a selective progestogen with a unique retroprogesterone structure, giving it high oral bioavailability. Official information states that it generally lacks other hormone-like effects, such as androgenic or estrogenic activity, which helps distinguish its profile from other synthetic progestins.

Q: Is Dirogest safe to use for older adults?

While there is no specific dosage recommendation for geriatric patients, its use as a component of Hormone Replacement Therapy (HRT) means its safety profile has been examined within a treatment context for post-menopausal women. This is the official basis for its use in this population.

Q: What happens if I use Dirogest for a long period of time?

Official regulatory documents address the long-term use of Dirogest by noting documented risks in certain contexts. These risks include the potential for progestogen-dependent neoplasms, such as meningioma, and the risk of Venous Thromboembolism (VTE) when the medicine is used in combination with estrogen for HRT.

Q: What type of conditions does Dirogest treat, besides the main one?

Dirogest is approved for several conditions related to a deficiency of progesterone. Therapeutic indications include irregular menstrual cycles, endometriosis, painful periods (dysmenorrhoea), and providing specific support in assisted reproductive technology (ART) procedures.

Q: What kind of studies or research evidence supports the use of Dirogest?

Clinical studies and regulatory documents summarize the findings that support Dirogest's approved uses. This evidence focuses on its observed effects for symptom relief in conditions like dysmenorrhea and its essential role in providing luteal phase support to aid in pregnancy.

Q: What should I know about taking Dirogest if I have diabetes?

Regulatory advisories for progestogens indicate that caution and professional medical oversight are necessary for patients who also have diabetes mellitus. This is because these types of medicines can potentially influence blood glucose control and sugar metabolism.

Q: Can people with high blood pressure use Dirogest?

Clinical data examining the medicine’s cardiovascular profile indicates that dydrogesterone appears largely neutral in terms of its overall effect on blood pressure. This finding is particularly noted when it is used in combination with estrogen for Hormone Replacement Therapy (HRT).

Q: Does Dirogest have any impact on fertility (general description)?

Dirogest is indicated for use in cases of infertility that are caused by a lack of luteal phase sufficiency. Its action provides the necessary progestational support to the uterine lining, which is essential for implantation and to sustain early pregnancy.

How to Store and Dispose of Dirogest

The storage and disposal instructions for Dirogest (dydrogesterone) are established in regulatory labeling to maintain product stability and safety.

Required Storage Conditions

• Temperature: The medicinal product must be stored at a temperature not exceeding 30 C. The product must not be frozen.
• Protection: The tablets must be kept in the original container to protect them from exposure to both light and moisture.
• Safety: Dirogest must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Dirogest should be disposed of in accordance with local requirements for pharmaceutical waste. General guidelines advise against discarding the medicine into household wastewater or sewers.